Use of Amantadine in the Evaluation of Response to Chemotherapy in Lung Cancer: a Pilot Study

Figures & data

Table 1. Patient demographics, type of lung cancer and staging.

Subject ID	Age (years)	Sex	Type of lung cancer (small-cell lung cancer or adenocarcinoma)	Stage
BMRT-01	67	Male	Adenocarcinoma	IV
BMRT-03	78	Male	Adenocarcinoma	IV
BMRT-04	53	Male	Adenocarcinoma	III
BMRT-05	68	Female	Adenocarcinoma	IV
BMRT-06	61	Female	Small-cell	III
BMRT-07	75	Male	Small-cell	IV
BMRT-08	63	Male	Adenocarcinoma	IV

Table 2. Plasma acetylamantadine concentration and disease assessment of lung cancer patients subsequent to one cycle of chemotherapy.

Subject ID	AA concentration (ng/ml)				Clinical assessment
	C1	C1	C2	C2
	2 h	4 h	2 h	4 h
BMRT-01	0.83	1.06	0.67	0.81	Disease progression
BMRT-03	n.d.	1.20	1.15	0.84	Stable disease for 1–2 months, then disease progression
BMRT-04	0.75	1.09	0.70	0.69	Partial disease remission
BMRT-05	1.51	1.07	1.04	1.52	Disease progression
BMRT-06	2.07	1.03	2.74	0.73	Partial disease remission
BMRT-07	1.04	1.43	1.04	1.82	Mixed response and progression
BMRT-08	0.51	0.68	1.16	0.55	Disease progression

Please note the plasma AA concentrations between 2 and 4 h after amantadine ingestion and prior to initial chemotherapy (C1) and prior to second scheduled cycle of chemotherapy (C2).

AA: Acetylamantadine; C1: Cycle 1; C2: Cycle 2; n.d.: Not determined.

Table 3. Plasma acetylamantadine concentration in responders and nonresponders to initial cycle of chemotherapy.

	4 h plasma acetylamantadine concentration (ng/ml)
	Responders (n = 3)	Nonresponders (n = 2)
C1D1	1.11	1.25
C2D1	0.75	1.67
Delta	-0.36	+0.42
Change	-32.4%	+33.6%

Responders are categorized as cases where there is partial disease remission (BMRT-04, BMRT-06) and stable disease (BMRT-03); nonresponders are categorized as cases where there is disease progression (BMRT-05, BMRT-07).